




This is Sustainability at Lundbeck

- We conduct our business activities in a way that support seven Sustainable Development Goals (SDGs) and mitigate significant risks and adverse impacts
- Our most fundamental contribution to a sustainable development is our medical treatments and the good health and well-being they bring to people
- We take a leading role in climate action and we promote an ethical, safe and inclusive culture in our operation and our value chain



2020 Lundbeck Sustainability highlights



Ranked #4 globally on the Net Promoter Score measuring patient groups' willingness to work with and recommend the company



Launched partnership with IHP * on product donations



New science-based climate target for entire value chain approved



68% recycling of solvents in production



Global Diversity & Inclusion Forum recommendations from employees adopted



Achieved "ESG Industry Top Rated" by Sustainalytics

^{*} International Health Partners

ESG ratings and indices in 2020

Lundbeck has significantly improved its ESG ratings in 2020














^{*} Sustainalytics, a leading independent provider of ESG and corporate governance ratings, research and analysis, has provided this Top Rated Badge which is based on Sustainalytics' proprietary ESG Risk Rating information. 24 February 2021.

Global health and well-being Access to brain health for all



- Our treatments reach more than 7 million people everyday living with brain diseases worldwide
- One of the few companies in the world that focus exclusively on this unmet need
- We have a responsibility not just to develop treatments and cures but also to help patients access them
- For many years, Lundbeck has worked to enhance cultural acceptance of brain diseases
- We advocate for improving mental health parity and reduce stigma – and support disease awareness and offer education



Global health and well-being

Access to brain health for all



Access to Brain Health Strategy

Lundbeck's Access to Brain Health Strategy aspirations reflect four Right to Health principles*



Availability

We leverage our specialist knowledge to address the burden of brain diseases and continue to make medicines available.



Accessibility

We promote the accessibility of our medicines by addressing discriminatory, physical, economical and informational barriers.



Acceptability

We improve mental health parity, reduce stigma, support national suicide prevention efforts and enhance cultural acceptability of brain diseases.



Good Quality

We provide high-quality medicinal products, safeguard patient safety and combat counterfeit medicine.

^{*}Inspired by the WHO and OHCHR "Factsheet No. 31 - The Right to Health".

Global health and well-being

New partnership on medicine donation










- In 2020, we entered into a new global mental healthcare partnership with International Health Partners (IHP)
- International Health Partners (IHP) is a UK-based charity that coordinates the safe and responsible donation of medical products from the healthcare industry

"We are delighted to be able to offer our first targeted mental health program through the partnership with Lundbeck. Our collaboration will lighten the burden for those living with poor mental health and help to change perceptions of these complex and often stigmatized conditions."

Adele Paterson CEO, International Health Partners





Staff member at Anera clinic, Lebanon.

Committed to innovation and availability Supporting the global community









- We remain committed to brain health which goes against the trend of shrinking research programs in psychiatric and neurological disorders in larger drug firms
- The Lundbeck Foundation* awarded scientific grants of EUR 60 million for biomedical research focused on the brain in 2020
- In 2020, Lundbeck contributed to the AMR Action Funds' ambition to raise USD 1 billion to combat antimicrobial resistance

"Antimicrobial resistance is a universal problem that we are pleased to help solve through this Fund. However, the pharmaceutical industry cannot avert crises like this one alone, so we need other institutions and policymakers to act as well. We all have an important role to play."

Deborah Dunsire, President and CEO of Lundbeck



Business ethics

Sustaining an ethical culture



- We are committed to creating a strong ethical culture and our Code of Conduct is the foundation
- It helps us navigate decisions with a broader perspective and steer us towards making a positive impact
- A key element in transparency is disclosure of interactions' transfer of value
- In 2020, we disclosed the value of 26,729 interactions with healthcare professionals across 36 countries



LUNDBECK'S COMPLIANCE PROGRAM

Documents, training, monitoring and governance are the elements that ensure we are doing the right thing, continually improve processes and sustain a compliance culture.

Access to Medicine Index 2021 – priority topics Lundbeck Reference Index

Technical areas		ATM priority topics	Lundbeck Sustainability Report 2020
A	Governance of Access	Responsible business practices Governance and strategy	Our sustainability strategy p. 6 Sustaining an ethical culture, p. 13-14 Access to brain health for all, p. 8-10 Governance and compliance p. 24-25
В	Research and Development	Access planning Product development Building R&D capacity	Access to medicine, p. 22 Access to brain health for all, p. 8-10 This is sustainability at Lundbeck. p. 5
С	Product delivery	Equitable access strategies Intellectual property strategy Quality and supply Licensing quality Registration Product donations Health system strengthening Inclusive business model Local manufacturing	Access to brain health for all, p. 8-10 Pricing, p. 22 Safeguarding patients, p. 9 Product quality p. 22 Clinical trials p. 25 Combating counterfeit products, p. 22 Transparent interactions, p. 24 About the IHP partnership p. 10

Source: Access to Medicine (ATM) Index Methodology 2021

Facts and figures to support our progress

Our Factbook offers sustainability analysts detailed facts, figures and references on how we govern, manage and monitor sustainability at Lundbeck.

The Factbook covers Environmental, Social and Governance (ESG) issues.

14%

Reductions in carbon emissions in 2020



Access to Medicine Index 2021 - diseases

Lundbeck's disease areas

- NCD's included in the 2021 Access to Medicine Index include several diseases in Lundbeck's diseases area:
 - Anxiety disorders, Bipolar disorder, Migraine, Schizophrenia, Unipolar depressive disorder, Alzheimer's disorder (new in 2021)
- This reflects that mental health and neurological diseases are very wide spread in all countries
- Most disease are included due to being top-ten high DALY burdens for non-communicable diseases in countries in scope
- As an example, more than 790 million people roughly 10% of the world's population - are living with a mental health disorder*

Included in ATM 2021

82 diseases, conditions and pathogens, including high-burden communicable diseases, non-communicable diseases, neglected tropical diseases, maternal & neonatal health conditions and priority pathogens.

Non-Communicable Diseases

Alzheimer's disease		
Anxiety disorders		
Asthma		
Bipolar disorder		
Cancer‡		
Chronic obstructive pulmonary		
disease (COPD)		
Diabetes mellitus		
Endometriosis		
Epilepsy		
Hypertensive heart disease		
Ischaemic heart disease		
Kidney diseases		
Migraine		
Schizophrenia		
Sickle cell disease		
Stroke		
Unipolar depressive disorders		

^{*} The Lancet (2018), GBD 2017 Disease and Injury Incidence and Prevalence Collaborators

Inclusive and safe working conditions A shared responsibility













- We are adamant that everyone at Lundbeck should feel safe and included when they come to work
- It is a shared responsibility to make sure our work environment is inclusive, safe and a great place to work for all
- Ideas and innovative approaches from diverse employees are needed to develop our company and accelerate our impact
- This year we took a bottom-up approach and established a global D&I Forum with 32 employees as members, representing 15 different locations from all functional areas



Climate action and circularity Stepping up on climate action









- Lundbeck sets new 15-year climate target, towards achieving net-zero carbon emissions across the entire value chain
- The new science based 15-year climate target, includes a detailed action plan to reduce emissions, approved by the Science Based Targets initiative (SBTi)
- We will collaborate with our suppliers and mobilize employees across the organization to identify reduction measures
- Applying circular economy principles is also a fundamental part of achieving our climate targets



3 ELEMENTS IN LUNDBECK'S NEW CLIMATE TARGET

- Commit to carbon neutrality no later than 2050
- Further reduce carbon emissions from production and fleet drastically by almost two-thirds over the next 15 years
- Work with our suppliers and customers to reduce our carbon footprint outside our premises by nearly a fifth over the next 15 years


70%

WE HAVE CUT DEEP ALREADY

Since 2006, we have reduced our ${\rm CO_2}$ emissions from our production by more than 70%

Where do our climate emissions come from?

Total CO₂e emissions in 2019 in entire value chain



Sustainability targets

Issue	2021 target	2020	target	SDG impac	t
Access to brain health	Ensure all disease awareness sponsorships within psychiatry measurably support suicide prevention or mental health awareness Donate treatment for at least 900 patients through new product donation partnerships in low- and middle-income countries	⊘	Engage all Lundbeck offices in local World Mental Health Day activities Establish a product donation partnership	3 GOOD HEALTH AND WELL-BEING	
Business ethics	Annual Code of Conduct training completed by all employees at work globally Increase proportion of healthcare professionals supporting disclosure of collaborations compared to the previous reporting year	⊘	Annual Code of Conduct training completed by all employees at work globally Work to increase proportion of healthcare professionals supporting disclosure of collaborations compared to the previous reporting year	PEACE, JUSTICE AND STRONG INSTITUTIONS	
Climate action	Reduce total carbon footprint across own operations, supply and distribution in line with our Science-Based Target	⊘	Reduce CO ₂ emission by 4% in 2020 compared to 2019 Obtain 'Science Based Targets initiative (SBTi)' approval of new climate target	13 GUMATE ACTION	
Environmental management	Recycle 60% of the solvents used in chemical production Recycle 62% of all general waste	⊘	Recycle 55% of the solvents used in chemical production Zero environmental incidents with an impact on the environment	12 RESPONSIBLE CONSUMPTION AND PRODUCTION	
Diversity and inclusion	Build an inclusive organization with a first initiative focusing on unconscious bias across the organization Maintain an overall equal gender split for people managers globally	②	Strive to maintain an overall equal gender split for people managers globally	10 REDUCED INEQUALITIES	5 GENDER EQUALITY

Reduce lost time accident frequency ≤ 5

8 DECENT WORK AND ECONOMIC GROWTH



Health and safety



Reduce lost time accident frequency ≤ 5

Sustainability Accounting Standard Board (SASB) Topical Reference Index

SASB Sustainability Disclosure Topics	Lundbeck Sustainability Report 2020			
Safety of Clinical Trial Participants	Clinical trials, p. 25			
Access to Medicines	 Access to brain health for all, p. 8-10 Access to medicine, p. 22 			
Affordability & Pricing	 Access to brain health for all, p. 8-10 Pricing, p. 22 			
Drug Safety	Patient safety, p. 22Product quality, p. 22			
Counterfeit Drugs	Combating counterfeit products, p. 22			
Ethical Marketing	 Sustaining an ethical culture, p. 13-14 Promotional activities, p. 22 			
Employee Recruitment, Development & Retention	 A shared responsibility, p. 15-16 Working at Lundbeck, p. 23 			
Supply Chain Management	 Sustaining an ethical culture, p. 13-14 Working standards in our value chain, p.23 Supplier and third party due diligence, p.24 Audits and monitoring, p.25 			
Business Ethics	 Sustaining an ethical culture, p. 13-14 Governance and compliance p. 24-25 			

SASB Materiality Map®

- Healthcare sector
- Biotechnology & Pharmaceuticals
- Version 2018-10